Category: Affinivax

GSK bolsters vaccines division with $3.3bn swoop on Affinivax

Affinivax, GlaxoSmithKline, M&A, News, pneumococcal disease, R&D, Sales and Marketing, Vaccine / May 31, 2022 May 31, 2022

GlaxoSmithKline has agreed a $3.3 billion takeover of US biotech Affinivax, buying a pneumococcal vaccine candidate that is aiming to break into a market that for years has been dominated by Pfizer’s Prevnar franchise. GSK said it is paying $2.1 billion upfront for Cambridge, Massachusetts-based Affinivax, with another $1.2 billion in potential development milestones, to …

GSK bolsters vaccines division with $3.3bn swoop on Affinivax Read More »

PharmaShots Weekly Snapshots (July 12 – 16, 2021)

AcelRx, Affinivax, Aguettant, Alexion, Aragen, Astellas, Bayer, Bio-Thera, Biogen, Caribou, Eli Lilly, ExCellThera, Galapagos, Heat Biologics, Hepion, Hologic, Hutchmed, Incyte, Innovent, Ionis, Ipsen, IRLAB, Janssen, Johnson & Johnson, Menagen, Novartis, Novo Nordisk, ProBioGen, Seagen, Skyhawk, Strongbridge, Takeda, Vir, Weekly Snapshot / July 16, 2021 July 16, 2021

Eli Lilly Signs an Agreement with Banner Alzheimer’s Institute to Evaluate Donanemab in P-III TRAILBLAZER-ALZ 3 Trial for Alzheimer’s Disease Published: July 16, 2021 | Tags: Eli Lilly, Banner Alzheimer’s Institute, Donanemab, P-III, TRAILBLAZER-ALZ 3 Trial, Alzheimer Disease AcelRx Signs a License Agreement with Aguettant to Commercialize Dzuveo in EU and for Two Pre-Filled Syringe …

PharmaShots Weekly Snapshots (July 12 – 16, 2021) Read More »

Shot in the arm for Affinivax as it challenges Pfizer’s Prevnar

Affinivax, Astellas, Merck & Co, News, Pfizer, Prevnar 13, PREVNAR 20, R&D, V114, Vaccine / July 14, 2021 July 14, 2021

Already facing one rival to its blockbuster pneumococcal vaccine Prevnar, Pfizer could have another to contend with, after Affinivax reported positive phase 2 results with its ASP3772 candidate – plus a new breakthrough designation from the FDA. Last year, Pfizer made almost $6 billion from its Prevnar 13 vaccine, which covers 13 common serotypes of …

Shot in the arm for Affinivax as it challenges Pfizer’s Prevnar Read More »